Use of daratumumab drug formulation for subcutaneous administration in multiple myeloma therapy: Literature review and clinical observation

Cover Page

Cite item

Full Text

Abstract

Study of the molecular pathogenesis of multiple myeloma led to development and introduction of antitumor agents with new mechanisms of action and their combinations into clinical practice. According to several trials, use of anti-CD38 monoclonal antibody daratumumab as part of triplet therapies at an early stage leads to deep and long-term antitumor response, achievement of MRD-negative status, and, as a result, increased survival and improved prognosis in all patient subgroups. High effectiveness of daratumumab subcutaneous formulation close to intravenous formulation has favorable safety profile, short administration time and low rate of infusion reactions which improves patients’ quality of life, affects their treatment compliance, and decreases healthcare costs.

We present a clinical observation of a 60-year-old patient with newly diagnosed multiple myeloma who previously underwent treatment for another lymphoproliferative disorder which included autologous hematopoietic stem cell transplantation leading to complete and long-term remission. After 9 intravenous daratumumab infusions (with recommended dose of 16 mg/kg) in accordance to the D-Rd regimen, evaluation of antitumor effect and consideration of socially active lifestyle of the patient, daratumumab formulation for intravenous administration was replaced with subcutaneous formulation of fixed dose 1800 mg. Further deepening of the antitumor response was observed along with manageable safety profile and absence of significant adverse events which allowed to maintain intercourse intervals and improve the patient’s quality of life.

About the authors

P. A. Zeynalova

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

ORCID iD: 0000-0003-1564-424X

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Bld. 2, 8 Trubetskaya St., Moscow 119991

Russian Federation

O. L. Timofeeva

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0000-0002-6229-7300

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Russian Federation

Yu. E. Ryabukhina

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

Author for correspondence.
Email: gemonk.yur@mail.ru
ORCID iD: 0000-0001-8443-8816

Yulia Evgenyevna Ryabukhina

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Russian Federation

F. M. Abbasbeyli

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0000-0002-2359-0547

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Russian Federation

N. A. Kupryshina

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0001-8509-0954

24 Kashirskoe Shosse, 115522 Moscow

Russian Federation

A. G. Zhukov

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0000-0001-5353-8857

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Russian Federation

T. T. Valiev

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

ORCID iD: 0000-0002-1469-2365

Bld. 2, 8 Trubetskaya St., Moscow 119991

Russian Federation

References

  1. L. Mendeleeva.P., Votyakova O.M., Rekhtina I.G. et al. Multiple myeloma. Clinical recommendations. Sovremennaya oncologiya = Modern Oncology 2020;22(4):6–28. doi: 10.26442/18151434.2020.4.200457
  2. Kuehl W.M., Bergsagel P.L. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012;122(10):3456–63. doi: 10.1172/JCI61188
  3. Attal M., Lauwers-Cances V., Hulin C. et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 2017;376(14):1311–20. doi: 10.1056/NEJMoa1611750
  4. Stewart A.K., Rajkumar S.V., Dimopoulos M.A. et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015;372:142–52. doi: 10.1056/NEJMoa1411321
  5. Moreau P., Masszi T., Grzasko N. et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;374(17):1621–34. doi: 10.1056/NEJMoa1516282
  6. Bessmeltsev S.S. CD38 antibodies in the patients with relapses/refractory multiple myeloma. Vestnik gematologii = Bulletin of Hematology 2018;14(3):5–18.
  7. Morandi F., Airoldi I., Marimpietri D. et al. CD38, a receptor with multi-functional activities: from modulatory functions on regulatory cell subsets and extracellular vesicles, to a target for therapeutic strategies. Cells 2019;8(12):1527. doi: 10.3390/cells8121527
  8. Van de Donk N.W., Janmaat M.L., Mutis T. et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev 2016;270(1):95–112. doi: 10.1111/imr.12389
  9. Van der Veer M.S., de Weers M., van Kessel B. et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 2011;96(2):284–90. doi: 10.3324/haematol.2010.030759
  10. Van de Donk N.W.C.J., Richardson P.G., Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood 2018;131(1):13–29. doi: 10.1182/blood-2017-06-740944
  11. Overdijk M.B., Jansen J.H.M., Nederend M. et al. The therapeutic CD38 monoclonal antibody Daratumumab induces programmed cell death via Fcγ receptor-mediated cross-linking. J Immunol 2016;197(3):807–13. doi: 10.4049/jimmunol.1501351
  12. Zhang K., Desai A., Zeng D. et al. Magic year for multiple myeloma therapeutics: key takeaways from the ASH 2015 annual meeting. Oncotarget 2017;8(6):10748–59. doi: 10.18632/oncotarget.13314
  13. Lonial S., Weiss B.M., Usmani S.Z. et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016;387(10027): 1551–60. doi: 10.1016/S0140-6736(15)01120-4
  14. Mateos M.V., Dimopoulos M.A., Cavo M. et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 2018;378(6):518–28. doi: 10.1056/NEJMoa1714678
  15. Dimopoulos M., San Miguel J., Belch A. et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica 2018;103(12):2088–96. doi: 10.3324/haematol.2018.194282
  16. Palumbo A., Chanan-Khan A., Weisel K. et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2016;375(8):754–66. doi: 10.1056/NEJMoa1606038
  17. Facon T., Kumar S., Plesner T. et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 2019;380(22):2104–15. doi: 10.1056/NEJMoa1817249
  18. Voorhees P.M., Kaufman J.L., Laubach J. et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 2020;136(8):936–45. doi: 10.1182/blood.2020005288
  19. Moreau P., Attal M., Hulin C. et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 2019;394(10192):29–38. doi: 10.1016/S0140-6736(19)31240-1
  20. Kim K., Phelps M.A. Clinical pharmacokinetics and pharmacodynamics of daratumumab. Clin Pharmacokinetic 2023;62(6):789–806. doi: 10.1007/s40262-023-01240-8
  21. Instructions for the medical use of the drug Darzalex, LP-004367. Date of last update: 12/27/2022.
  22. DARZALEX (daratumumab) injection, for intravenous use [package insert]. Horsham, PA: Janssen Biotech, Inc., 2019.
  23. Frost G.I. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fuid administration. Expert Opin Drug Deliv 2007;4(4):427–40. doi: 10.1517/17425247.4.4.427
  24. Chandran Suja V., Qi Q.M., Halloran K. et al. A biomimetic chip to assess subcutaneous bioavailability of monoclonal antibodies in humans. PNAS Nexus 2023;2(10):pgad317. doi: 10.1093/pnasnexus/pgad317
  25. Locke K.W., Maneval D.C., LaBarre M.J. ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20. Drug Deliv 2019;26(1):98–106. doi: 10.1080/10717544.2018.1551442
  26. Bittner B., Richter W., Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs 2018;32(5):425–40. doi: 10.1007/s40259-018-0295-0
  27. Instructions for the medical use of the drug Darzalex, LP-008138 from 06.05.2022. Date of last update: 13.09.2023.
  28. DARZALEX FASPROTM (daratumumab and hyaluronidase-fihj) injection, for subcutaneous use [prescribing information]. Horsham, PA: Janssen Biotech, Inc., 2020.
  29. Luo M.M., Usmani S.Z., Mateos M.V. et al. Exposure-response and population pharmacokinetic analyses of a novel subcutaneous formulation of daratumumab administered to multiple myeloma patients. J Clin Pharmacol 2021;61(5):614–27. doi: 10.1002/jcph.1771
  30. San-Miguel J., Usmani S.Z., Mateos M.V. et al. Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO). Haematologica 2021;106(6):1725–32. doi: 10.3324/haematol.2019.243790
  31. Usmani S.Z, Nahi H., Legiec W. et al. Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma. Haematologica 2022;107(10):2408–17. doi: 10.3324/haematol.2021.279459
  32. Chari A., Rodriguez-Otero P., McCarthy H. et al. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study. Br J Haematol 2021;192(5):869–78. doi: 10.1111/bjh.16980
  33. Sanchez L., Richter J., Cho H.J. et al. Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma. Ther Adv Hematol 2021;12:2040620720987075. doi: 10.1177/2040620720987075
  34. Soefje S.A., Carpenter C., Carlson K. et al. Clinical administration characteristics of subcutaneous and intravenous administration of daratumumab in patients with multiple myeloma at Mayo Clinic infusion centers. JCO Oncol Pract 2023;19(4):e542–e9. doi: 10.1200/OP.22.00421
  35. Kumar S.K., Dimopoulos M.A., Kastritis E. et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia 2017;31(11):2443–8. doi: 10.1038/leu.2017.138
  36. Facon T., Cook G., Usmani S.Z. et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia 2022;36(4):1066–77. doi: 10.1038/s41375-021-01488-8
  37. Weisel K., Kumar S., Moreau P. et al. P09 Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): updated analysis of the phase 3 MAIA study. HemaSphere 2023;7(S2):14–5. doi: 10.1097/01.HS9.0000936164.84357.ed

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 ABV-Press

License URL: https://mdonco.abvpress.ru/jour/about/editorialPolicies
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-81466 от  03.08.2021.